Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04169841 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

Study acronym: GUIDE2REPAIR
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Feb 10, 2023 to Aug 10, 2027 Trial status: Recruiting to Active, Not Recruiting · Completion date: Jun 10, 2029 to Aug 10, 2027 · Site details revised at 8 of 8 sitesv5 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Jun 10, 2029 to Aug 10, 2027
    • Site details revised at 8 of 8 sites
  2. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Mar 1, 2020 to Feb 10, 2023 · Study sites: 7 to 8 · Completion date: Mar 1, 2023 to Jun 10, 2029 · 1 morev4 Show 4 more changesShow less
    • Primary completion date: Mar 1, 2020 to Feb 10, 2023
    • Study sites: 7 to 8
    • Completion date: Mar 1, 2023 to Jun 10, 2029
    • Start date changed from estimate of Mar 1, 2020 to Feb 10, 2020
  3. Start date: Jan 1, 2020 to Mar 1, 2020 Primary completion date: Jan 1, 2020 to Mar 1, 2020 · Completion date: Jan 1, 2023 to Mar 1, 2023v3 Show 2 more changesShow less
    • Primary completion date: Jan 1, 2020 to Mar 1, 2020
    • Completion date: Jan 1, 2023 to Mar 1, 2023
  4. Study description shortened, about 18 wordsv2 See this version in full on ClinicalTrials.gov ↗
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study propose to generate a clinical trial based on precision medicine to evaluate the use of immunotherapy in patients with altered homologous recombination repair genes and without progression after prior targeted therapy.
Trial Details
NCT Number NCT04169841
Lead Sponsor Centre Georges Francois Leclerc
Collaborators: AstraZeneca
Conditions Immunotherapy
Enrollment 270 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov